[1]
|
Baum, P., Schmid, R., Ittrich, C., Rust, W., Fundel-Clemens, K., Siewert, S., et al. (2010) Phenocopy—A Strategy to Qualify Chemical Compounds during Hit-to-Lead and/or Lead Optimization. PLoS ONE, 5, e14272. https://doi.org/10.1371/journal.pone.0014272
|
[2]
|
Lescai, F. and Franceschi, C. (2010) The Impact of Phenocopy on the Genetic Analysis of Complex Traits. PLoS ONE, 5, e11876. https://doi.org/10.1371/journal.pone.0011876
|
[3]
|
Bousfiha, A., Jeddane, L., Picard, C., Ailal, F., Bobby-Gaspar, H., Al-Herz, W., et al. (2018) The 2017 IUIS Phenotypic Classification for Primary Immunodeficiencies. Journal of Clinical Immunology, 38, 129-143. https://doi.org/10.1007/s10875-017-0465-8
|
[4]
|
Picard, C., Bobby-Gaspar, H., Al-Herz, W., Bousfiha, A., Casanova, J.L., Chatila, T., et al. (2018) International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. Journal of Clinical Immunology, 38, 96-128. https://doi.org/10.1007/s10875-017-0464-9
|
[5]
|
Clark, D.P., Pazdernik, N.J. and McGehee, M.R. (2019) Mutations and Repair. In: Molecular Biology, Elsevier, Amsterdam, 832-879. https://doi.org/10.1016/B978-0-12-813288-3.00026-4
|
[6]
|
Milholland, B., Dong, X., Zhang, L., Hao, X., Suh, Y. and Vijg, J. (2017) Differences between Germline and Somatic Mutation Rates in Humans and Mice. Nature Communications, 8, Article No. 15183. https://doi.org/10.1038/ncomms15183
|
[7]
|
Nabhani, S., Honscheid, A., Oommen, P.T., Fleckenstein, B., Schaper, J., Kuhlen, M., et al. (2014) A Novel Homozygous Fas Ligand Mutation Leads to Early Protein Truncation, Abrogation of Death Receptor and Reverse Signaling and a Severe Form of the Autoimmune Lymphoproliferative Syndrome. Clinical Immunology, 155, 231-237. https://doi.org/10.1016/j.clim.2014.10.006
|
[8]
|
Li, P., Huang, P., Yang, Y., Hao, M., Peng, H. and Li, F. (2016) Updated Understanding of Autoimmune Lymphoproliferative Syndrome (ALPS). Clinical Reviews in Allergy & Immunology, 50, 55-63. https://doi.org/10.1007/s12016-015-8466-y
|
[9]
|
Oliveira, J.B., Bleesing, J.J., Dianzani, U., Fleisher, T.A., Jaffe, E.S., Lenardo, M.J., et al. (2010) Revised Diagnostic Criteria and Classification for the Autoimmune Lymphoproliferative Syndrome (ALPS): Report from the 2009 NIH International Workshop. Blood, 116, e35-e40. https://doi.org/10.1182/blood-2010-04-280347
|
[10]
|
Palmisani, E., Miano, M., Micalizzi, C., Calvillo, M., Pierri, F., Terranova, P., et al. (2019) Clinical Features and Therapeutic Challenges of Cytopenias Belonging to Alps and Alps-Related (ARS) Phenotype. British Journal of Haematology, 184, 861-864. https://doi.org/10.1111/bjh.15178
|
[11]
|
Holzelova, E., Vonarbourg, C., Stolzenberg, M.C., Arkwright, P.D., Selz, F., Prieur, A.M., et al. (2004) Autoimmune Lymphoproliferative Syndrome with Somatic Fas Mutations. The New England Journal of Medicine, 351, 1409-1418. https://doi.org/10.1056/NEJMoa040036
|
[12]
|
Dowdell, K.C., Niemela, J.E., Price, S., Davis, J., Hornung, R.L., Oliveira, J.B., et al. (2010) Somatic FAS Mutations Are Common in Patients with Genetically Undefined Autoimmune Lymphoproliferative Syndrome. Blood, 115, 5164-5169. https://doi.org/10.1182/blood-2010-01-263145
|
[13]
|
Martínez-Feito, A., Melero, J., Mora-Díaz, S., Rodríguez-Vigil, C., Elduayen, R., González-Granado, L.I., et al. (2016) Autoimmune Lymphoproliferative Syndrome Due to Somatic FAS Mutation (ALPS-sFAS) Combined with a Germline Caspase-10 (CASP10) Variation. Immunobiology, 221, 40-47. https://doi.org/10.1016/j.imbio.2015.08.004
|
[14]
|
García-García, G.M., Bureo-Dacal, J.C., Suárez-Varela Pineda, S. and Elduayen Izaguirre, R. (2015) Adult Onset Autoimmune Lymphoproliferative Syndrome Due to Somatic FAS Mutation. Internal Medicine Journal, 45, 462-464. https://doi.org/10.1111/imj.12714
|
[15]
|
Matson, D.R. and Yang, D.T. (2019) Autoimmune Lymphoproliferative Syndrome: An Overview. Archives of Pathology & Laboratory Medicine. https://doi.org/10.5858/arpa.2018-0190-RS
|
[16]
|
Rieux-Laucat, F., Magérus-Chatinet, A. and Neven, B. (2018) The Autoimmune Lymphoproliferative Syndrome with Defective FAS or FAS-Ligand Functions. Journal of Clinical Immunology, 38, 558-568. https://doi.org/10.1007/s10875-018-0523-x
|
[17]
|
Barzaghi, F., Minniti, F., Mauro, M., Bortoli, M.D., Balter, R., Bonetti, E., et al. (2019) ALPS-Like Phenotype Caused by ADA2 Deficiency Rescued by Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 9, 2767. https://doi.org/10.3389/fimmu.2018.02767
|
[18]
|
Rao, V.K., Price, S., Perkins, K., Aldridge, P., Tretler, J., Davis, J., et al. (2009) Use of Rituximab for Refractory Cytopenias Associated with Autoimmune Lymphoproliferative Syndrome (ALPS). Pediatric Blood & Cancer, 52, 847-852. https://doi.org/10.1002/pbc.21965
|
[19]
|
Oliveira, J.B., Bidere, N., Niemela, J.E., Zheng, L., Sakai, K., Nix, C.P., et al. (2007) NRAS Mutation Causes a Human Autoimmune Lymphoproliferative Syndrome. Proceedings of the National Academy of Sciences, 104, 8953-8958. https://doi.org/10.1073/pnas.0702975104
|
[20]
|
Calvo, K.R., Price, S., Braylan, R.C., Oliveira, J.B., Lenardo, M., Fleisher, T.A., et al. (2015) JMML and RALD (Ras-Associated Autoimmune Leukoproliferative Disorder): Common Genetic Etiology Yet Clinically Distinct Entities. Blood, 125, 2753-2758. https://doi.org/10.1182/blood-2014-11-567917
|
[21]
|
Olson, M.F. and Marais, R. (2000) Ras Protein Signalling. Seminars in Immunology, 12, 63-73. https://doi.org/10.1006/smim.2000.0208
|
[22]
|
Ma, P., Magut, M., Faller, D.V. and Chen, C.Y. (2002) The Role of Ras in T Lymphocyte Activation. Cellular Signalling, 14, 849-859. https://doi.org/10.1016/S0898-6568(02)00029-3
|
[23]
|
Ragotte, R.J., Dhanrajani, A., Pleydell-Pearce, J., Del Bel, K.L., Tarailo-Graovac, M., van Karnebeek, C., et al. (2017) The Importance of Considering Monogenic Causes of Au-toimmunity: A Somatic Mutation in KRAS Causing Pediatric Rosai-Dorfman Syndrome and Systemic Lupus Erythematosus. Clinical Immunology, 175, 143-146. https://doi.org/10.1016/j.clim.2016.12.006
|
[24]
|
Scheffzek, K., Ahmadian, M.R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., et al. (1997) The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants. Science, 277, 333-338. https://doi.org/10.1126/science.277.5324.333
|
[25]
|
Malumbres, M. and Barbacid, M. (2003) RAS Oncogenes: The First 30 Years. Nature Reviews Cancer, 3, 459-465. https://doi.org/10.1038/nrc1097
|
[26]
|
Giacaman, A., Bauzá-Alonso, A., Salinas-Sanz, J.A., Dapena-Díaz, J.L., Ramos-Asensio, R., Ferrés-Ramis, L., et al. (2018) Cutaneous Involvement in an 8-Year-Old Boy with Ras-Associated Autoimmune Leucoproliferative Disorder (RALD). Clinical and Experimental Dermatology, 43, 913-916. https://doi.org/10.1111/ced.13668
|
[27]
|
Takagi, M., Shinoda, K., Piao, J., Mitsuiki, N., Takagi, M., Matsuda, K., et al. (2011) Autoimmune Lymphoproliferative Syndrome-Like Disease with Somatic KRAS Mutation. Blood, 117, 2887-2890. https://doi.org/10.1182/blood-2010-08-301515
|
[28]
|
Wang, W., Zhou, Y., Zhong, L., Wang, L., Tang, X., Ma, M., et al. (2019) RAS-Associated Autoimmune Leukoproliferative Disease (RALD) Manifested with Early-Onset SLE-Like Syndrome: A Case Series of RALD in Chinese Children. Pediatric Rheumatology, 17, 55. https://doi.org/10.1186/s12969-019-0346-1
|
[29]
|
Toyoda, H., Deguchi, T., Iwamoto, S., Kihira, K., Hori, H., Komada, Y., et al. (2018) Weekly Rituximab Followed by Monthly Rituximab Treatment for Autoimmune Disease Associated with RAS-Associated Autoimmune Leukoproliferative Disease. Journal of Pediatric Hematology/Oncology, 40, e516-e518. https://doi.org/10.1097/MPH.0000000000001276
|
[30]
|
Federici, S., Vanoni, F., Ben-Chetrit, E., Cantarini, L., Frenkel, J., Goldbach-Mansky, R., et al. (2019) An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptor-Associated Periodic Fever Syndromes, and Cryopyrin-Associated Periodic Syndrome. The Journal of Rheumatology, 46, 429-436. https://doi.org/10.3899/jrheum.180056
|
[31]
|
Bertoni, A., Carta, S., Baldovini, C., Penco, F., Balza, E., Borghini, S., et al. (2019)A Novel Knock-In Mouse Model of Cryopyrin-Associated Periodic Syndromes with Development of Amyloidosis: Therapeutic Efficacy of Proton Pump Inhibitors. Journal of Allergy and Clinical Immunology, 2019, S0091674919307572.
|
[32]
|
Booshehri, L.M. and Hoffman, H.M. (2019) CAPS and NLRP3. Journal of Clinical Immunology, 39, 277-286. https://doi.org/10.1007/s10875-019-00638-z
|
[33]
|
Keddie, S., Parker, T., Lachmann, H.J. and Ginsberg, L. (2018) Cryopyrin-Associated Periodic Fever Syndrome and the Nervous System. Current Treatment Options in Neurology, 20, 43. https://doi.org/10.1007/s11940-018-0526-1
|
[34]
|
Gattorno, M., Hofer, M., Federici, S., Vanoni, F., Bovis, F., Aksentijevich, I., et al. (2019) Classification Criteria for Autoinflammatory Recurrent Fevers. Annals of the Rheumatic Diseases, 78, 1025-1032. https://doi.org/10.1136/annrheumdis-2019-215048
|
[35]
|
Behringer, J., Ryan, M., Miller, M. and Jaju, A. (2019) Magnetic Resonance Imaging Findings in a Patient with Cryopyrin-Associated Periodic Syndrome: A Rare Hereditary Multi-System Inflammatory Disorder. The Neuroradiology Journal. https://doi.org/10.1177/1971400919863712
|
[36]
|
Kilic, H., Sahin, S., Duman, C., Adrovic, A., Barut, K., Turanli, E.T., et al. (2019) Spectrum of the Neurologic Manifestations in Childhood-Onset Cryopyrin-Associated Periodic Syndrome. European Journal of Paediatric Neurology, 23, 466-472. https://doi.org/10.1016/j.ejpn.2019.03.006
|
[37]
|
Nakagawa, K., Gonzalez-Roca, E., Souto, A., Kawai, T., Umebayashi, H., Campistol, J.M., et al. (2015) Somatic NLRP3 Mosaicism in Muckle-Wells Syndrome. A Genetic Mechanism Shared by Different Phenotypes of Cryopyrin-Associated Periodic Syndromes. Annals of the Rheumatic Diseases, 74, 603-610. https://doi.org/10.1136/annrheumdis-2013-204361
|
[38]
|
Lasigliè, D., Mensa-Vilaro, A., Ferrera, D., Caorsi, R., Penco, F., Santamaria, G., et al. (2017) Cryopyrin-Associated Periodic Syndromes in Italian Patients: Evaluation of the Rate of Somatic NLRP3 Mosaicism and Phenotypic Characterization. The Journal of Rheumatology, 44, 1667-1673. https://doi.org/10.3899/jrheum.170041
|
[39]
|
Ozen, S. (2018) What’s New in Autoinflammation? Pediatric Nephrology, 34, 2449-2456. http://link.springer.com/10.1007/s00467-018-4155-4
|
[40]
|
Eskola, V., Pohjankoski, H., Kroger, L., Aalto, K., Latva, K. and Korppi, M. (2018) Cryopyrin-Associated Periodic Syndrome in Early Childhood Can Be Successfully Treated with Interleukin-1 Blockades. Acta Paediatrica, 107, 577-580. https://doi.org/10.1111/apa.14217
|
[41]
|
Elmi, A.A., Wynne, K., Cheng, I.L., Eleftheriou, D., Lachmann, H.J., Hawkins, P.N., et al. (2019) Retrospective Case Series Describing the Efficacy, Safety and Cost-Effectiveness of a Vial-Sharing Programme for Canakinumab Treatment for Paediatric Patients with Cryopyrin-Associated Periodic Syndrome. Pediatric Rheumatology, 17, 36. https://doi.org/10.1186/s12969-019-0335-4
|
[42]
|
Marchica, C., Zawawi, F., Basodan, D., Scuccimarri, R. and Daniel, S.J. (2018) Resolution of Unilateral Sensorineural Hearing Loss in a Pediatric Patient with a Severe Phenotype of Muckle-Wells Syndrome Treated with Anakinra: A Case Report and Review of the Literature. Journal of Otolaryngology—Head & Neck Surgery, 47, 9. https://doi.org/10.1186/s40463-018-0256-0
|
[43]
|
Iida, Y., Wakiguchi, H., Okazaki, F., Nakamura, T., Yasudo, H., Kubo, M., et al. (2019) Early Canakinumab Therapy for the Sensorineural Deafness in a Family with Muckle-Wells Syndrome Due to a Novel Mutation of NLRP3 Gene. Clinical Rheumatology, 38, 943-948. https://doi.org/10.1007/s10067-018-4331-8
|
[44]
|
Brogan, P.A., Hofer, M., Kuemmerle-Deschner, J.B., Koné-Paut, I., Roesler, J., Kallinich, T., et al. (2019) Rapid and Sustained Long-Term Efficacy and Safety of Canakinumab in Patients with Cryopyrin-Associated Periodic Syndrome Ages Five Years and Younger. Arthritis & Rheumatology, 71, 1955-1963. https://doi.org/10.1002/art.41004
|
[45]
|
Mulders-Manders, C.M., Kanters, T.A., van Daele, P.L.A., Hoppenreijs, E., Legger, G.E., van Laar, J.A.M., et al. (2018) Decreased Quality of Life and Societal Impact of Cryopyrin-Associated Periodic Syndrome Treated with Canakinumab: A Questionnaire Based Cohort Study. Orphanet Journal of Rare Diseases, 13, 59. https://doi.org/10.1186/s13023-018-0799-1
|
[46]
|
Kontro, M., Kuusanmaki, H., Eldfors, S., Burmeister, T., Andersson, E.I., Bruserud, O., et al. (2014) Novel Activating STAT5B Mutations as Putative Drivers of T-Cell Acute Lymphoblastic Leukemia. Leukemia, 28, 1738-1742. https://doi.org/10.1038/leu.2014.89
|
[47]
|
Maurer, B., Nivarthi, H., Wingelhofer, B., Pham, H.T.T., Schlederer, M., Suske, T., et al. (2019) High Activation of STAT5A Drives Peripheral T-Cell Lymphoma and Leukemia. Haematologica, haematol.2019.216986. https://doi.org/10.3324/haematol.2019.216986
|
[48]
|
Lorenzini, T., Dotta, L., Giacomelli, M., Vairo, D. and Badolato, R. (2017) STAT Mutations as Program Switchers: Turning Primary Immunodeficiencies into Autoimmune Diseases. Journal of Leukocyte Biology, 101, 29-38. https://doi.org/10.1189/jlb.5RI0516-237RR
|
[49]
|
Hwa, V. (2016) STAT5B Deficiency: Impacts on Human Growth and Immunity. Growth Hormone & IGF Research, 28, 16-20. https://doi.org/10.1016/j.ghir.2015.12.006
|
[50]
|
Haapaniemi, E.M., Kaustio, M., Rajala, H.L.M., van Adrichem, A.J., Kainulainen, L., Glumoff, V., et al. (2015) Autoimmunity, Hypogammaglobulinemia, Lymphoproliferation, and Mycobacterial Disease in Patients with Activating Mutations in STAT3. Blood, 125, 639-648. https://doi.org/10.1182/blood-2014-04-570101
|
[51]
|
Ma, C.A., Xi, L., Cauff, B., DeZure, A., Freeman, A.F., Hambleton, S., et al. (2017) Somatic STAT5b Gain-of-Function Mutations in Early Onset Nonclonal Eosinophilia, Urticaria, Dermatitis, and Diarrhea. Blood, 129, 650-653. https://doi.org/10.1182/blood-2016-09-737817
|
[52]
|
Blake, S.J. and Teng, M.W.L. (2014) Role of IL-17 and IL-22 in Autoimmunity and Cancer. Actas Dermo-Sifiliográficas, 105, 41-50. https://doi.org/10.1016/S0001-7310(14)70017-1
|
[53]
|
Amatya, N., Garg, A.V. and Gaffen, S.L. (2017) IL-17 Signaling: The Yin and the Yang. Trends in Immunology, 38, 310-322. https://doi.org/10.1016/j.it.2017.01.006
|
[54]
|
Ferre, E.M.N., Rose, S.R., Rosenzweig, S.D., Burbelo, P.D., Romito, K.R., Niemela, J.E., et al. (2016) Redefined Clinical Features and Diagnostic Criteria in Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy. JCI Insight, 1, pii: e88782. https://doi.org/10.1172/jci.insight.88782
|
[55]
|
Capalbom, D., De Martinom, L., Giardino, G., Di Mase, R., Di Donato, I., Parenti, G., et al. (2012) Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy: Insights into Genotype-Phenotype Correlation. International Journal of Endocrinology, 2012, Article ID: 353250. https://doi.org/10.1155/2012/353250
|
[56]
|
Guo, C.J., Leung, P.S.C., Zhang, W., Ma, X. and Gershwin, M.E. (2018) Theimmunobiology and Clinical Features of Type 1 Autoimmune Polyglandular Syndrome (APS-1). Autoimmunity Reviews, 17, 78-85. https://doi.org/10.1016/j.autrev.2017.11.012
|
[57]
|
Yamazaki, Y., Yamada, M., Kawai, T., Morio, T., Onodera, M., Ueki, M., et al. (2014) Two Novel Gain-of-Function Mutations of STAT1 Responsible for Chronic Mucocutaneous Candidiasis Disease: Impaired Production of IL-17A and IL-22, and the Presence of Anti-IL-17F Autoantibody. The Journal of Immunology, 193, 4880-4887. https://doi.org/10.4049/jimmunol.1401467
|
[58]
|
Sarkadi, A.K., Taskó, S., Csorba, G., Tóth, B., Erdos, M. and Maródi, L. (2014) Autoantibodies to IL-17A May Be Correlated with the Severity of Mucocutaneous Candidiasis in APECED Patients. Journal of Clinical Immunology, 34, 181-193. https://doi.org/10.1007/s10875-014-9987-5
|
[59]
|
Ng, W.F., von Delwig, A., Carmichael, A.J., Arkwright, P.D., Abinun, M., Cant, A.J., et al. (2010) Impaired TH17 Responses in Patients with Chronic Mucocutaneous Candidiasis with and without Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy. Journal of Allergy and Clinical Immunology, 126, 1006-1015.e4. https://doi.org/10.1016/j.jaci.2010.08.027
|
[60]
|
Eyerich, K., Foerster, S., Rombold, S., Seidl, H.P., Behrendt, H., Hofmann, H., et al. (2008) Patients with Chronic Mucocutaneous Candidiasis Exhibit Reduced Production of Th17-Associated Cytokines IL-17 and IL-22. Journal of Investigative Dermatology, 128, 2640-2645. https://doi.org/10.1038/jid.2008.139
|
[61]
|
Karner, J., Meager, A., Laan, M., Maslovskaja, J., Pihlap, M., Remm, A., et al. (2013) Anti-Cytokine Autoantibodies Suggest Pathogenetic Links with Autoimmune Regulator Deficiency in Humans and Mice: Anti-Cytokine Autoantibodies in Mice and Humans. Clinical & Experimental Immunology, 171, 263-272. https://doi.org/10.1111/cei.12024
|
[62]
|
Kisand, K., Boe-Wolff, A.S., Podkrajsek, K.T., Tserel, L., Link, M., Kisand, K.V., et al. (2010) Chronic Mucocutaneous Candidiasis in APECED or Thymoma Patients Correlates with Autoimmunity to Th17-Associated Cytokines. Journal of Experimental Medicine, 207, 299-308. https://doi.org/10.1084/jem.20091669
|
[63]
|
Wu, U.I. and Holland, S.M. (2015) Host Susceptibility to Non-Tuberculous Mycobacterial Infections. The Lancet Infectious Diseases, 15, 968-980. https://doi.org/10.1016/S1473-3099(15)00089-4
|
[64]
|
Browne, S.K. and Holland, S.M. (2010) Immunodeficiency Secondary to Anticytokine Autoantibodies. Current Opinion in Allergy and Clinical Immunology, 10, 534-541. https://doi.org/10.1097/ACI.0b013e3283402b41
|
[65]
|
Yasamut, U., Thongkum, W., Moonmuang, S., Sakkhachornphop, S., Chaiwarith, R., Praparattanapan, J., et al. (2019) Neutralizing Activity of Anti-Interferon-γ Autoantibodies in Adult-Onset Immunodeficiency Is Associated with Their Binding Domains. Frontiers in Immunology, 10, 1905. https://doi.org/10.3389/fimmu.2019.01905
|
[66]
|
Merkel, P.A., Lebo, T. and Knight, V. (2019) Functional Analysis of Anti-Cytokine Autoantibodies Using Flow Cytometry. Frontiers in Immunology, 10, 1517. https://doi.org/10.3389/fimmu.2019.01517
|
[67]
|
Chi, C.Y., Lin, C.H., Ho, M.W., Ding. J.Y., Huang, W.C., Shih, H.P., et al. (2016) Clinical Manifestations, Course, and Outcome of Patients with Neutralizing Anti-Interferon-γ Autoantibodies and Disseminated Nontuberculous Mycobacterial Infections. Medicine, 95, e3927. https://doi.org/10.1097/MD.0000000000003927
|
[68]
|
Jutivorakool, K., Sittiwattanawong, P., Kantikosum, K., Hurst, C., Kumtornrut, C., Asawanonda, P., et al. (2018) Skin Manifestations in Patients with Adult-Onset Immunodeficiency Due to Anti-Interferon-Gamma Autoantibody: A Relationship with Systemic Infections. Acta Dermato-Venereologica, 98, 742-747. https://doi.org/10.2340/00015555-2959
|
[69]
|
Hong, G.H., Ortega-Villa, A.M., Hunsberger, S., Chetchotisakd, P., Anunnatsiri, S., Mootsikapun, P., et al. (2019) Natural History and Evolution of Anti-Interferon-γ Autoantibody-Associated Immunodeficiency Syndrome in Thailand and the US. Clinical Infectious Diseases, ciz786. https://doi.org/10.1093/cid/ciz786
|
[70]
|
Garbers, C., Aparicio-Siegmund, S. and Rose-John, S. (2015) The IL-6/gp130/STAT3 Signaling Axis: Recent Advances towards Specific Inhibition. Current Opinion in Immunology, 34, 75-82. https://doi.org/10.1016/j.coi.2015.02.008
|
[71]
|
Tanaka, T., Narazaki, M. and Kishimoto, T. (2014) IL-6 in Inflammation, Immunity, and Disease. Cold Spring Harbor Perspectives in Biology, 6, a016295. https://doi.org/10.1101/cshperspect.a016295
|
[72]
|
Puel, A., Picard, C., Lorrot, M., Pons, C., Chrabieh, M., Lorenzo, L., et al. (2008) Recurrent Staphylococcal Cellulitis and Subcutaneous Abscesses in a Child with Autoantibodies against IL-6. The Journal of Immunology, 180, 647-654. https://doi.org/10.4049/jimmunol.180.1.647
|
[73]
|
Fosgerau, K., Galle, P., Hansen, T., Albrechtsen, A., Rieper, C. de L., Pedersen, B.K., et al. (2010) Interleukin-6 Autoantibodies Are Involved in the Pathogenesis of a Subset of Type 2 Diabetes. Journal of Endocrinology, 204, 265-273. https://doi.org/10.1677/JOE-09-0413
|
[74]
|
Karner, J., Pihlap, M., Ranki, A., Krohn, K., Trebusak-Podkrajsek, K., Bratanic, N., et al. (2016) IL-6-Specific Autoantibodies among APECED and Thymoma Patients. Immunity, Inflammation and Disease, 4, 235-243. https://doi.org/10.1002/iid3.109
|
[75]
|
Hansen, M.B., Svenson, M., Diamant, M. and Bendtzen, K. (1991) Anti-Interleukin-6 Antibodies in Normal Human Serum. Scandinavian Journal of Immunology, 33, 777-781. https://doi.org/10.1111/j.1365-3083.1991.tb02552.x
|
[76]
|
Barcenas-Morales, G., Cortes-Acevedo, P. and Doffinger, R. (2019) Anticytokine Autoantibodies Leading to Infection: Early Recognition, Diagnosis and Treatment Options. Current Opinion in Infectious Diseases, 32, 330-336. https://doi.org/10.1097/QCO.0000000000000561
|
[77]
|
Kumar, A., Abdelmalak, B., Inoue, Y. and Culver, D.A. (2018) Pulmonary Alveolar Proteinosis in Adults: Pathophysiology and Clinical Approach. The Lancet Respiratory Medicine, 6, 554-565. https://doi.org/10.1016/S2213-2600(18)30043-2
|
[78]
|
Kitamura, N., Ohkouchi, S., Tazawa, R., Ishii, H., Takada, T., Sakagami, T., et al. (2019) Incidence of Autoimmune Pulmonary Alveolar Proteinosis Estimated Using Poisson Distribution. ERJ Open Research, 5, Article ID: 00190-2018. https://doi.org/10.1183/23120541.00190-2018
|
[79]
|
Bonella, F., Bauer, P.C., Griese, M., Ohshimo, S., Guzman, J. and Costabel, U. (2011) Pulmonary Alveolar Proteinosis: New Insights from a Single-Center Cohort of 70 Patients. Respiratory Medicine, 105, 1908-1916. https://doi.org/10.1016/j.rmed.2011.08.018
|
[80]
|
Kiani, A., Parsa, T., Adimi-Naghan, P., Dutau, H., Razavi, F., Farzanegan, B., et al. (2018) An Eleven-Year Retrospective Cross-Sectional Study on Pulmonary Alveolar Proteinosis. Advances in Respiratory Medicine, 86, 7-12. https://doi.org/10.5603/ARM.2018.0003
|
[81]
|
McCarthy, C., Carey, B. and Trapnell, B.C. (2019) Blood Testing for Differential Diagnosis of Pulmonary Alveolar Proteinosis Syndrome. Chest, 155, 450-452. https://doi.org/10.1016/j.chest.2018.11.002
|
[82]
|
Semionov, A. and Kosiuk, J. (2019) Interstitial Lung Disease as a Late Complication of Pulmonary Alveolar Proteinosis. Radiology Case Reports, 14, 572-575. https://doi.org/10.1016/j.radcr.2019.02.011
|
[83]
|
Seymour, J.F. and Presneill, J.J. (2002) Pulmonary Alveolar Proteinosis: Progress in the First 44 Years. American Journal of Respiratory and Critical Care Medicine, 166, 215-235. https://doi.org/10.1164/rccm.2109105
|
[84]
|
Abdelmalak, B.B., Khanna, A.K., Culver, D.A. and Popovich, M.J. (2015) Therapeutic Whole-Lung Lavage for Pulmonary Alveolar Proteinosis: A Procedural Update. Journal of Bronchology & Interventional Pulmonology, 22, 251-258. https://doi.org/10.1097/LBR.0000000000000180
|
[85]
|
Tazawa, R., Ueda, T., Abe, M., Tatsumi, K., Eda, R., Kondoh, S., et al. (2019) Inhaled GM-CSF for Pulmonary Alveolar Proteinosis. The New England Journal of Medicine, 38, 923-932. https://doi.org/10.1056/NEJMoa1816216
|
[86]
|
Sheng, G., Chen, P., Wei, Y., Chu, J., Cao, X. and Zhang, H.L. (2018) Better Approach for Autoimmune Pulmonary Alveolar Proteinosis Treatment: Inhaled or Subcutaneous Granulocyte-Macrophage Colony-Stimulating Factor: A Meta-Analyses. Respiratory Research, 19, 163. https://doi.org/10.1186/s12931-018-0862-4
|
[87]
|
Soyez, B., Borie, R., Menard, C., Cadranel, J., Chavez, L., Cottin, V., et al. (2018) Rituximab for Auto-Immune Alveolar Proteinosis, a Real Life Cohort Study. Respiratory Research, 19, 74. https://doi.org/10.1186/s12931-018-0780-5
|
[88]
|
Banday, A.Z., Kaur, A., Jindal, A.K., Rawat, A. and Singh, S. (2019) An Update on the Genetics and Pathogenesis of Hereditary Angioedema. Genes & Diseases, S2352304219300455. https://doi.org/10.1016/j.gendis.2019.07.002
|
[89]
|
Otani, I.M. and Banerji, A. (2017) Acquired C1 Inhibitor Deficiency. Immunology and Allergy Clinics of North America, 37, 497-511. https://doi.org/10.1016/j.iac.2017.03.002
|
[90]
|
Zanichelli, A., Suffritti, C., Cicardi, M. and Perricone, R. (2014) C1 Inhibitor Autoantibodies. In: Autoantibodies, Elsevier, Amsterdam, 699-705. https://linkinghub.elsevier.com/retrieve/pii/B9780444563781000824 https://doi.org/10.1016/B978-0-444-56378-1.00082-4
|
[91]
|
Mészáros, T., Füst, G., Farkas, H., Jakab, L., Temesszentandrási, G., Nagy, G., et al. (2010) C1-Inhibitor Autoantibodies in SLE. Lupus, 19, 634-638. https://doi.org/10.1177/0961203309357059
|
[92]
|
Bova, M., De Feo, G., Parente, R., De Pasquale, T., Gravante, C., Pucci, S., et al. (2018) Hereditary and Acquired Angioedema: Heterogeneity of Pathogenesis and Clinical Phenotypes. International Archives of Allergy and Immunology, 175, 126-135. https://doi.org/10.1159/000486312
|
[93]
|
Craig, T.J., Bernstein, J.A., Farkas, H., Bouillet, L. and Boccon-Gibod, I. (2014) Diagnosis and Treatment of Bradykinin-Mediated Angi-oedema: Outcomes from an Angioedema Expert Consensus Meeting. International Archives of Allergy and Immunology, 165, 119-127. https://doi.org/10.1159/000368404
|
[94]
|
Zanichelli, A., Azin, G.M., Wu, M.A., Suffritti, C., Maggioni, L., Caccia, S., et al. (2017) Diagnosis, Course, and Management of Angioedema in Patients with Acquired C1-Inhibitor Deficiency. The Journal of Allergy and Clinical Immunology: In Practice, 5, 1307-1313. https://doi.org/10.1016/j.jaip.2016.12.032
|
[95]
|
Levi, M., Cohn, D., Zeerleder, S., Dziadzio, M. and Longhurst, H. (2019 Long-Term Effects upon Rituximab Treatment of Acquired Angioedema Due to C1-Inhibitor Deficiency. Allergy, 74, 834-840. https://doi.org/10.1111/all.13686
|
[96]
|
Dreyfus, D.H., Na, C.R., Randolph, C.C., Kearney, D., Price, C. and Podell, D. (2014) Successful Rituximab B Lymphocyte Depletion Therapy for Angioedema Due to Acquired C1 Inhibitor Protein Deficiency: Association with Reduced C1 Inhibitor Protein Autoantibody Titers. The Israel Medical Association Journal, 16, 315-316.
|
[97]
|
Tekin, Z.E., Yener, G.O. and Yüksel, S. (2018) Acquired Angioedema in Juvenile Systemic Lupus Erythematosus: Case-Based Review. Rheumatology International, 38, 1577-1584. https://doi.org/10.1007/s00296-018-4088-z
|
[98]
|
Ferreira, V.P., Pangburn, M.K. and Cortés, C. (2010) Complement Control Protein Factor H: The Good, the Bad, and the Inadequate. Molecular Immunology, 47, 2187-2197. https://doi.org/10.1016/j.molimm.2010.05.007
|
[99]
|
Sénant, M. and Dragon-Durey, M.A. (2019) Anti-Factor H Autoantibodies Assay by ELISA. In: Autoantibodies, Springer, Berlin, 191-196. http://link.springer.com/10.1007/978-1-4939-8949-2_15 https://doi.org/10.1007/978-1-4939-8949-2_15
|
[100]
|
Franchini, M. (2015) Atypical Hemolytic Uremic Syndrome: From Diagnosis to Treatment. Clinical Chemistry and Laboratory Medicine, 53, 1679-1688. https://doi.org/10.1515/cclm-2015-0024
|
[101]
|
Zhang, K., Lu, Y., Harley, K.T. and Tran, M.H. (2017) Atypical Hemolytic Uremic Syndrome: A Brief Review. Hematology Reports, 9, 62-67. https://doi.org/10.4081/hr.2017.7053
|
[102]
|
Raina, R., Krishnappa, V., Blaha, T., Kann, T., Hein, W., Burke, L., et al. (2019) Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment: Update on Atypical Hemolytic Uremic Syndrome. Therapeutic Apheresis and Dialysis, 23, 4-21. https://doi.org/10.1111/1744-9987.12763
|
[103]
|
Vondrák, K. and Seeman, T. (2018) Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome Due to Complement Factor H Hybrid Gene: A Case Report. Transplantation Proceedings, 50, 967-970. https://doi.org/10.1016/j.transproceed.2018.02.012
|
[104]
|
Sahutoglu, T., Basturk, T., Sakaci, T., Koc, Y., Ahbap, E., Sevinc, M., et al. (2016) Can Eculizumab Be Discontinued in aHUS? Case Report and Review of the Literature. Medicine, 95, e4330. https://doi.org/10.1097/MD.0000000000004330
|
[105]
|
Puraswani, M., Khandelwal, P., Saini, H., Saini, S., Gurjar, B.S., Sinha, A., et al. (2019) Clinical and Immunological Profile of Anti-Factor H Antibody Associated Atypical Hemolytic Uremic Syndrome: A Nationwide Database. Frontiers in Immunology, 10, 1282. https://doi.org/10.3389/fimmu.2019.01282
|
[106]
|
Deville, C., Garrouste, C., Coppo, P., Evrard, B., Lautrette, A. and Heng, A.E. (2016) Efficacy of Rituximab and Plasmapharesis in an Adult Patient with Antifactor H Autoantibody-Associated Hemolytic Uremic Syndrome: A Case Report and Literature Review. Medicine, 95, e5007. https://doi.org/10.1097/MD.0000000000005007
|
[107]
|
Zaman, M., Huissoon, A., Buckland, M., Patel, S., Alachkar, H., Edgar, J.D., et al. (2019) Clinical and Laboratory Features of Seventy-Eight UK Patients with Good’s Syndrome (Thymoma and Hypogammaglobulinaemia): Good’s Syndrome in the UK. Clinical & Experimental Immunology, 195, 132-138. https://doi.org/10.1111/cei.13216
|
[108]
|
Burbelo, P.D., Browne, S.K., Sampaio, E.P., Giaccone, G., Zaman, R., Kristosturyan, E., et al. (2010) Anti-Cytokine Autoantibodies Are Associated with Opportunistic Infection in Patients with Thymicneoplasia. Blood, 116, 4848-4858. https://doi.org/10.1182/blood-2010-05-286161
|
[109]
|
Tamburello, A., Castelnovo, L., Faggioli, P., Bompane, D., Brando, B., Gatti, A., et al. (2019) Good’s Syndrome, a Rare Form of Acquired Immunodeficiency Associated with Thymomas. Clinical Practice, 9, 51-54. https://doi.org/10.4081/cp.2019.1112
|
[110]
|
Herrera-Sánchez, D.A., León-Pedroza, J.I., Vargas-Camano, M.E. and Castrejón- Vázquez, M.I. (2017) Good’s Syndrome. Report of Case. Revista Alergia Mexico, 64, 235-240. https://doi.org/10.29262/ram.v64i2.194
|
[111]
|
Kawamura, T., Naito, T., Kobayashi, H., Nakashima, K., Omori, S., Wakuda, K., et al. (2019) Acquired Immunodeficiency Associated with Thymoma: A Case Report. BMC Cancer, 19, 762. https://doi.org/10.1186/s12885-019-5980-y
|
[112]
|
Multani, A., Gomez, C.A. and Montoya, J.G. (2018) Prevention of Infectious Diseases in Patients with Good Syndrome. Current Opinion in Infectious Diseases, 31, 267-277. https://doi.org/10.1097/QCO.0000000000000473
|
[113]
|
Sveinsson, O., Piehl, F., Aspegren, O. and Hietala, M.A. (2019) Successful Combined Treatment with Thymectomy, Rituximab and Tocilizumab for Severe Thymoma-Associated Multi Autoimmune Syndrome. Journal of Neuroimmunology, 336, Article ID: 577028. https://doi.org/10.1016/j.jneuroim.2019.577028
|